CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Delcath Systems to Present Phase 2 Breast Cancer Trial at ESMO 2026

By Public Technologies
  • Delcath Systems will present Phase 2 breast and colorectal cancer trial updates at ESMO Congress in Madrid on October 24, 2026.
  • The breast cancer study compares melphalan hepatic delivery followed by standard therapy with standard therapy alone; no results were disclosed.
  • A separate retrospective analysis published in September 2026 evaluated CHEMOSAT hepatic delivery in 12 patients with liver-dominant metastatic uveal melanoma.
  • Most patients experienced tumor shrinkage or disease stabilization; three experienced serious adverse events, with no treatment-related deaths.
  • An independent poster scheduled for October 24 will compare hepatic delivery with immunotherapy against tebentafusp in liver-metastatic uveal melanoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610191601BIZWIRE_USPR_____20261019_BW169467) on October 19, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk